logo
  

Quoin Pharmaceuticals Prices Offering Of Approx. 4.1 Mln Shares At $1.6/Share; Stock Tanks

Quoin Pharmaceuticals, Ltd. (QNRX), Tuesday announced the pricing of offering of around 4.1 million shares, representing same amount of American Depository Shares or ADS, and warrants, at a combined price of $1.6 per share, to raise approximately $6.5 million.

The specialty pharmaceutical company intends to use the proceeds for corporate-related purposes.

The company stated that the warrants, Series D and Series E, would be exercisable immediately following the date of issuance and would expire in two years and five years, respectively, from their issuance.

The offering is expected to close on or about March 7.

Following the announcement, Quoin's stock is currently tumbling 44.48 percent, to $1.57 over the previous close of $2.9 on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Editors Pick
AbbVie (ABBV) Monday announced a collaboration and option-to-license agreement with Gilgamesh Pharmaceuticals, a clinical stage neuroscience biotech firm, to develop next-generation treatment approaches and unmet needs in psychiatric disorders. AbbVie noted that the first-generation compounds may... Healthwest Minerals, Inc. d/b/a Mt. Capra Products has recalled 1,506 boxes of Goat Milk Formula Recipe Kit, also urging consumers to immediately discontinue use of the product as infant formula. The firm does not recommend using this product for infants from 0-12 months of age. Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.

This week, we bring a mix of medical breakthroughs and setbacks. Lyko's MDMA therapy could become the first FDA-approved psychedelic treatment if all goes well as planned. A tragic loss occurred in Pfizer's Duchenne trial and a new study has raised concerns about ultra-processed foods. Find out why Long Beach declared a public health emergency and how Novavax's actions signal optimism.

View More Videos
Follow RTT